(RTTNews) - Medical technologies firm Teleflex Inc. (TFX) announced Thursday that its UroLift System for treating benign prostatic hyperplasia or BPH has received regulatory clearance in China. The ...

The committee concluded that UroLift is clinically effective, with sustained relief of lower urinary tract symptoms up to 5 years after treatment. It is implanted using a minimally invasive procedure.

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has unveiled groundbreaking results from the CLEAR study, the first head-to-head randomized controlled trial comparing the UroLift™ System with Rezūm™ ...

Teleflex announces favorable results for UroLift™ in treating BPH, showing higher patient satisfaction and better early recovery compared to Rezūm. Teleflex Incorporated announced new results from the ...

Teleflex (NYSE:TFX) reported new research from controlled and real-world studies of Prostatic Urethral Lift (PUL) procedure with its UroLift System to treat men with benign prostatic hyperplasia (BPH) ...

TEXARKANA, Texas — Benign prostatic hyperplasia — or BPH — is a common condition in men over 50 that causes the prostate to enlarge. The enlarged prostate pinches the urethra, which carries urine from ...

In a ground-breaking medical achievement, Nigeria has become the first country in West and Central Africa to successfully perform the UroLift procedure, a revolutionary treatment for benign prostate ...

Physician brings non-surgical outpatient prostate procedure to McLaren Northern Michigan, providing quicker recovery times. Featured in the 2021 issue of MyNorth Medical Insider. When Bryan Shumaker, ...

Source: Getty Images Patients who underwent the minimally invasive procedure had a 36%, 50%, and 44% improvement in IPSS, quality of life, and peak flow rate, respectively, at 5 years. Prostatic ...

The UroLift System (Teleflex Inc.) is used to do a prostatic urethral lift, a procedure that relieves lower urinary tract symptoms. It uses implants to pull excess prostatic tissue away from the ...